Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

NCT06580873 is registered in ClinicalTrials.gov with Saskatchewan Health Authority - Regina Area as lead sponsor.

NCT NCT06580873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06580873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
Lead sponsor
Saskatchewan Health Authority - Regina Area
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2024
Completion date
October 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection, opioid use disorder